Enhertu significantly improved IDFS compared to Kadcyla, with a 53% risk reduction in invasive disease or death in high-risk, ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback